DOCSLIB.ORG

Boster Antibodies) Anti-Actin Antibody (Monoclonal) Anti-AFP Antibody (Monoclonal) Anti-BAP1 Antibody (Monoclonal) Anti-Bcl-2 An

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Boster Antibodies) Anti-Actin Antibody (Monoclonal) Anti-AFP Antibody (Monoclonal) Anti-BAP1 Antibody (Monoclonal) Anti-Bcl-2 An boster antibodies) Anti-Actin Antibody (monoclonal) Anti-AFP Antibody (monoclonal) Anti-BAP1 Antibody (monoclonal) Anti-Bcl-2 Antibody (monoclonal) Anti-BIN1 Antibody (monoclonal) Anti-Calbindin-D Antibody (monoclonal) Anti-Calcineurin alpha Antibody (monoclonal) Anti-Caldesmon(smooth) Antibody (monoclonal) Anti-Calmodulin Antibody (monoclonal) Anti-Calponin Antibody (monoclonal) Anti-Catenin gamma(Plakoglobin) Antibody (monoclonal) Anti-Cathepsin D Antibody (monoclonal) Anti-Cathepsin L Antibody (monoclonal) Anti-CD3 Antibody (monoclonal) Anti-CD4 Antibody (monoclonal) Anti-CD8 Antibody (monoclonal) Anti-CDC25C Antibody (monoclonal) Anti-CDC6 Antibody (monoclonal) Anti-CDK4 Antibody (monoclonal) Anti-CDK6 Antibody (monoclonal) Anti-Cdk7/CAK Antibody (monoclonal) Anti-CEA Antibody (monoclonal) Anti-Cytokeratin Peptide 7 Antibody (monoclonal) Anti-Cytokeratin Peptide 18 Antibody (monoclonal) Anti-c-Myc Antibody (monoclonal) Anti-Collagen, Type III Antibody (monoclonal) Anti-Collagen, Type IV Antibody (monoclonal) Anti-Cyclin A Antibody (monoclonal) Anti-Cyclin D1 Antibody (monoclonal) Anti-Cyclin D2 Antibody (monoclonal) Anti-Desmin Antibody (monoclonal) Anti-Dystrophin Antibody (monoclonal) Anti-Elastin Antibody (monoclonal) Anti-Episialin, EMA Antibody (monoclonal) Anti-VEGFR2 Antibody (monoclonal) Anti-Filensin Antibody (monoclonal) Anti-GAP43 Antibody (monoclonal) Anti-Gelsolin Antibody (monoclonal) Anti-GFAP Antibody (monoclonal) Anti-Glucagon Antibody (monoclonal) Anti-HSP25 Antibody (monoclonal) Anti-HSP60 Antibody (monoclonal) Anti-HSP70 Antibody (monoclonal) Anti-HSP90 Antibody (monoclonal) Anti-Insulin Antibody (monoclonal) Anti-Involucrin Antibody (monoclonal) Anti-Laminin Antibody (monoclonal) Anti-MAP Kinase, Activated(Diphosphorylated ERK-1&2) Antibody (monoclonal) Anti-MAP1 Antibody (monoclonal) Anti-MAP2 Antibody (monoclonal) Anti-Mcm7 Antibody (monoclonal) Anti-P-Glycoprotein(MDR) Antibody (monoclonal) Anti-Mucin Gastric Antibody (monoclonal) Anti-Myoglobin Antibody (monoclonal) Anti-Myosin(Skeletal, Fast) Antibody (monoclonal) Anti-Myosin(Skeletal, Slow) Antibody (monoclonal) Anti-Myosin(Smooth) Antibody (monoclonal) Anti-N-Cadherin Antibody (monoclonal) Anti-NCAM Antibody (monoclonal) Anti-Nebulin Antibody (monoclonal) Anti-NF68 Antibody (monoclonal) Anti-NF200 Antibody (monoclonal) Anti-Nitric Oxide Synthase, Brain(1-181) NOS1 Antibody (monoclonal) Anti-p16INK4a/CDKN2 Antibody (monoclonal) Anti-p19INK4d Antibody (monoclonal) Anti-p27Kip1 Antibody (monoclonal) Anti-p34cdc2 Antibody (monoclonal) Anti-p53 Antibody (monoclonal) Anti-Pan-Cadherin Antibody (monoclonal) Anti-Paxillin Antibody (monoclonal) Anti-PCK Antibody (monoclonal) Anti-PCK-26 Antibody (monoclonal) Anti-PCNA Antibody (monoclonal) Anti-Phosphoserine Antibody (monoclonal) Anti-PKB alpha Antibody (monoclonal) Anti-PSTAIR Antibody (monoclonal) Anti-Smad4(DPC4) Antibody (monoclonal) Anti-Spectrin(alpha and beta) Antibody (monoclonal) Anti-Synaptophysin Antibody (monoclonal) Anti-Talin Antibody (monoclonal) Anti-Tau Antibody (monoclonal) Anti-Tenascin Antibody (monoclonal) Anti-Tropomyosin(36/39 kDa) Antibody (monoclonal) Anti-Tropomyosin(36kD) Antibody (monoclonal) Anti-Tropomyosin(Sarcomeric) Antibody (monoclonal) Anti-Troponin T Antibody (monoclonal) Anti-Tryptophan Hydroxylase Antibody (monoclonal) Anti-Tyrosine Hydroxylase Antibody (monoclonal) Anti-Vimentin Antibody (monoclonal) Anti-Vinculin Antibody (monoclonal) Anti-alpha-Actinin Antibody (monoclonal) Anti-alpha-Adaptin Antibody (monoclonal) Anti-alpha-Smooth Muscle Actin Antibody (monoclonal) Anti-alpha-Tubulin Antibody (monoclonal) Anti-beta-Amyloid Protein Antibody (monoclonal) Anti-beta-HCG Antibody (monoclonal) Anti-beta-Tubulin Antibody (monoclonal) Anti-gamma-Tubulin Antibody (monoclonal) Anti-beta-Actin Antibody (monoclonal) Anti-Fibronectin Antibody (monoclonal) Anti-mouse TNF alpha Antibody Anti-rat Interferon gamma Antibody Anti-human Interferon gamma Antibody Anti-human BCL-2 Antibody Anti-human EPO Antibody Anti-human FGF1 Antibody Anti-human FGF2 Antibody Anti-rat Growth Hormone Antibody Anti-human IL3 Antibody Anti-human IL4 Antibody Anti-human SCF Antibody Anti-human DDT Antibody Anti-human IL6 Antibody Anti-human IL7 Antibody Anti-human IL10 Antibody Anti-mouse IL10 Antibody Anti-rat IL10 Antibody Anti-mouse IL18 Antibody Anti-human CEACAM5 Antibody Anti-mouse IL17 Antibody Anti-human MIF Antibody Anti-mouse Prolactin Antibody Anti-human Transferrin Antibody Anti-human Growth Hormone Antibody Anti-mouse Growth Hormone Antibody Anti-human NGF Antibody Anti-human Survivin Antibody Anti-human Angiostatin K1-3 Antibody Anti-IL12 p40 Antibody Anti-CD30 Antibody Anti-VR1 Antibody Anti-ALOX5 Antibody Anti-FOXP3 Antibody Anti-Collagen III Antibody Anti-P Glycoprotein Antibody Anti-SCP3 Antibody Anti-TIE2 Antibody Anti-Angiopoietin 2 Antibody Anti-MUC2 Antibody Anti-PD1 Antibody Anti-ATM Antibody Anti-CBS Antibody Anti-Claudin 2 Antibody Anti-Claudin 5 Antibody Anti-Dicer Antibody Anti-Cyclin D2 Antibody Anti-IL3 Antibody Anti-IL13 Antibody Anti-IL13 Antibody Anti-MBD2 Antibody Anti-CD146 Antibody Anti-Midkine Antibody Anti-Survivin Antibody Anti-ATP2A1 Antibody Anti-ATP2A2 Antibody Anti-ATP2A3 Antibody Anti-KAT13A/SRC1 Antibody Anti-Occludin Antibody Anti-PKC delta Antibody Anti-SSH3BP1 Antibody Anti-alpha 2a Adrenergic Receptor Antibody Anti-Alkaline Phosphatase Antibody Anti-Alkaline Phosphatase Antibody Anti-Alkaline Phosphatase Antibody Anti-Angiopoietin 2 Antibody Anti-Annexin A1 Antibody Anti-Annexin IV Antibody Anti-Annexin V Antibody Anti-Apoptosis inhibitor 5 Antibody Anti-Aquaporin 1 Antibody Anti-ATF6 Antibody Anti-ATP5J Antibody Anti-Bax Antibody Anti-Bax Antibody Anti-BDNF Antibody Anti-Calretinin Antibody Anti-CCR5 Antibody Anti-CCR5 Antibody Anti-CCR5 Antibody Anti-CD22 Antibody Anti-CD40 Antibody Anti-CD40 Antibody Anti-CD40L Antibody Anti-CD44 Antibody Anti-CD44 Antibody Anti-GJB2 Antibody Anti-Connexin 43/GJA1 Antibody Anti-Connexin 43/GJA1 Antibody Anti-COX1/Cyclooxygenase 1 Antibody Anti-C Reactive Protein Antibody Anti-DUT Antibody Anti-FGF4 Antibody Anti-GAD67 Antibody Anti-GAP43 Antibody Anti-GST3/GST pi Antibody Anti-HIF-1-alpha Antibody Anti-HMGB4 Antibody Anti-Hsp40 Antibody Anti-INSL3 Antibody Anti-Integrin alpha 1 Antibody Anti-Integrin alpha 1 Antibody Anti-KCNN4 Antibody Anti-Lamin B1 Antibody Anti-MAPK1/3 Antibody Anti-Myelin Basic Protein Antibody Anti-Mitofusin 2 Antibody Anti-Morg1 Antibody Anti-Myeloperoxidase Antibody Anti-NCAM Antibody Anti-NGF Antibody Anti-BNIP3 Antibody Anti-NMDAR2A Antibody Anti-NMDAR2B Antibody Anti-NMDAR2B Antibody Anti-Nogo A Antibody Anti-NSE Antibody Anti-Neurotrophin 3 Antibody Anti-PKC alpha Antibody Anti-PLGF Antibody Anti-PMVK Antibody Anti-PP2A Antibody Anti-RAGE Antibody Anti-AMD1 Antibody Anti-Secretogranin 3 Antibody Anti-Sonic Hedgehog Antibody Anti-Sonic Hedgehog Antibody Anti-SMAD2/3 Antibody Anti-SOCS1 Antibody Anti-STAT1 Antibody Anti-TIMP2 Antibody Anti-TIMP3 Antibody Anti-TIMP4 Antibody Anti-TIMP4 Antibody Anti-TNF alpha Antibody Anti-VEGF Antibody Anti-Orexin Receptor 1 Antibody Anti-Fas Ligand Antibody Anti-SKP2 Antibody Anti-Lamin A+C Antibody Anti-FOXL2 Antibody Anti-SCYL1BP1 Antibody Anti-HSP60 Antibody Anti-STAT3 Antibody Anti-IFITM1 Antibody Anti-Caspase-2 Antibody Anti-SHP2 Antibody Anti-gamma Catenin Antibody Anti-gamma Catenin Antibody Anti-Cytochrome C Antibody Anti-CD95 Antibody Anti-Glucose Transporter GLUT1 Antibody Anti-MMP2 Antibody Anti-MMP16 Antibody Anti-CD18 Antibody Anti-NF-kB p65 Antibody Anti-Estrogen Receptor beta Antibody Anti-Topoisomerase II alpha Antibody Anti-HIF-2-alpha Antibody Anti-HIF-2-alpha Antibody Anti-OPCML Antibody Anti-CCR6 Antibody Anti-Chk2 Antibody Anti-HRH3 Antibody Anti-TNF Receptor I Antibody Anti-COX2/Cyclooxygenase 2 Antibody Anti-beta Catenin Antibody Anti-beta Catenin Antibody Anti-P2X3 Antibody Anti-Hsc70 Antibody Anti-Notch1 Antibody Anti-FGF8 Antibody Anti-XAF1 Antibody Anti-Rad51 Antibody Anti-Aquaporin 4 Antibody Anti-NMDAR1 Antibody Anti-Heparanase 1 Antibody Anti-RUNX2 Antibody Anti-Cyclin D2 Antibody Anti-NTE Antibody Anti-TdT Antibody Anti-liver FABP Antibody Anti-Aquaporin 5 Antibody Anti-Dopamine Receptor D1 Antibody Anti-Bcl-XL Antibody Anti-Cullin 4B Antibody Anti-PKC gamma Antibody Anti-SSX2 Antibody Anti-CXCR4 Antibody Anti-GFAP Antibody Anti-Cytokeratin 8 Antibody Anti-FGFR2 Antibody Anti-FGFR2 Antibody Anti-ROCK2 Antibody Anti-TNF Receptor II Antibody Anti-SCN1B Antibody Anti-Cyclin D1 Antibody Anti-LXR alpha Antibody Anti-LXR alpha Antibody Anti-Apolipoprotein A I Antibody Anti-TFPI2 Antibody Anti-APAF1 Antibody Anti-AKT1/2 Antibody Anti-Caspase-3(P10) Anti-Caspase-3(P10) Antibody Anti-S100 beta Antibody Anti-Lipoprotein lipase Antibody Anti-TNFAIP1 Antibody Anti-SDHA Antibody Anti-CD82 Antibody Anti-Caspase-8(P18) Antibody Anti-Phospholamban Antibody Anti-ERK2 Antibody Anti-ERK2 Antibody Anti-PUMA Antibody Anti-Decorin Antibody Anti-SNAP25 Antibody Anti-MTCO1 Antibody Anti-MTCO1 Antibody Anti-MTCO1 Antibody Anti-c-Fos Antibody Anti-PPAR gamma Antibody Anti-TrkA Antibody Anti-NPHS2 Antibody Anti-NPHS2 Antibody Anti-Actin Antibody Anti-Actin Antibody Anti-Muscarinic Acetylcholine Receptor 2 Antibody Anti-Hex Antibody Anti-Ly6al Antibody Anti-N Cadherin Antibody Anti-nNOS(neuronal) Antibody Anti-NOS2 Antibody Anti-SMAD 1/2/3/5 Antibody Anti-VEGFD Antibody Anti-Angiopoietin 1 Antibody Anti-CD34 Antibody Anti-Cytokeratin 19 Antibody Anti-Cardiac FABP Antibody Anti-FAF1 Antibody Anti-GAPDH Antibody Anti-GAPDH Antibody Anti-Hsp90 alpha
Load more

Recommended publications
  • Large-Scale Serum Protein Biomarker Discovery in Duchenne Muscular Dystrophy
    Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy Yetrib Hathouta, Edward Brodyb, Paula R. Clemensc,d, Linda Cripee, Robert Kirk DeLisleb, Pat Furlongf, Heather Gordish- Dressmana, Lauren Hachea, Erik Henricsong, Eric P. Hoffmana, Yvonne Monique Kobayashih, Angela Lortsi, Jean K. Mahj, Craig McDonaldg, Bob Mehlerb, Sally Nelsonk, Malti Nikradb, Britta Singerb, Fintan Steeleb, David Sterlingb, H. Lee Sweeneyl, Steve Williamsb, and Larry Goldb,1 aResearch Center for Genetic Medicine, Children’s National Medical Center, Washington, DC 20012; bSomaLogic, Inc., Boulder, CO 80301; cNeurology Service, Department of Veteran Affairs Medical Center, Pittsburgh, PA 15240; dUniversity of Pittsburgh, Pittsburgh, PA 15213; eThe Heart Center, Nationwide Children’s Hospital, The Ohio State University, Columbus, OH 15213; fParent Project Muscular Dystrophy, Hackensack, NJ 07601; gDepartment of Physical Medicine and Rehabilitation, University of California Davis School of Medicine, Davis, CA 95618; hDepartment of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, IN 46202; iThe Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229; jDepartment of Pediatrics, University of Calgary, Alberta Children’s Hospital, Calgary, AB, Canada T3B 6A8; kDivision of Pulmonary Sciences and Critical Care Medicine, University of Colorado Denver, Aurora, CO 80045; and lDepartment of Pharmacology & Therapeutics, University of Florida College of Medicine, Gainesville, FL 32610 Contributed
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Acemannan Stimulates Bone Sialoprotein, Osteocalcin, Osteopon- Tin and Osteonectin Expression in Periodontal Ligament Cells in V
    Original Article บ ท วิ ท ย า ก า ร Acemannan Stimulates Bone Sialoprotein, Osteocalcin, Osteopon- tin and Osteonectin Expression in Periodontal Ligament Cells in Vitro Pintu-on Chantarawaratit1,2,4, Polkit Sangvanich3 and Pasutha Thunyakitpisal2,4 1Department of Orthodontics, Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand 2Dental Biomaterials Program, Graduate School, Chulalongkorn University, Bangkok, Thailand 3Department of Chemistry, Faculty of Science, Chulalongkorn University, Bangkok, Thailand 4Research Unit of Herbal Medicine and Natural Products of Dental Application, Department of Anatomy, Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand Correspondence to: Pasutha Thunyakitpisal, Department of Anatomy, Faculty of Dentistry, Chulalongkorn University, 34, Henri-Dunant Rd, Patumwan, Bangkok 10330, Thailand Email: [email protected] Abstract The periodontium is composed of both soft and hard tissues, thus hard tissue regeneration is one of the most important processes in periodontal regeneration. Bone sialoprotein, osteocalcin, osteopontin and osteonectin are non- collagenous matrix proteins which play vital roles in the mineralization of hard tissue. Recent studies have demonstrated that acemannan, a polysaccharide extracted from Aloe vera gel, upregulated the expression of proteins involved in hard tissue regeneration. This study investigated effect of acemannan on bone sialoprotein, osteocalcin, osteopontin and osteonectin expression in human periodontal ligament cells. Primary periodontal ligament cells were isolated from impacted third molars and then treated with acemannan in vitro. The mRNA expression of bone sialoprotein and osteocalcin and the protein levels of osteopontin and osteonectin were determined using reverse transcription-polymerase chain reaction and western blot analysis, respectively. One-way analysis of variance and Dunnett multiple comparisons were performed to analyze the data.
    [Show full text]
  • CHAPTER 41 Target Genes: Bone Proteins 719
    CHAPTER 41 Target Genes: Bone Proteins 719 45. Bellows CG, Reimers SM, Heersche JN 1999 Expression of 61. Price PA, Williamson MK, Lothringer JW 1981 Origin of the mRNAs for type-I collagen, bone sialoprotein, osteocalcin, vitamin K-dependent bone protein found in plasma and its and osteopontin at different stages of osteoblastic differentia- clearance by kidney and bone. J Biol Chem 256:12760–12766. tion and their regulation by 1,25-dihydroxyvitamin D3. Cell 62. Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, Tissue Res 297:249–259. Smith E, Bonadio J, Goldstein S, Gundberg C, Bradley A, 46. Broess M, Riva A, Gerstenfeld LC 1995 Inhibitory effects of Karsenty G 1996 Increased bone formation in osteocalcin- 1,25(OH)2 vitamin D3 on collagen type I, osteopontin, and deficient mice. Nature 382:448–452. osteocalcin gene expression in chicken osteoblasts. J Cell 63. Chenu C, Colucci S, Grano M, Zigrino P, Barattolo R, Biochem 57:440–451. Zambonin G, Baldini N, Vergnaud P, Delmas PD, Zallone AZ 47. Yoon K, Buenaga R, Rodan GA, Prince CW, Butler WT 1994 Osteocalcin induces chemotaxis, secretion of matrix pro- 1987 Tissue specificity and developmental expression of teins, and calcium-mediated intracellular signaling in human rat osteopontin. Biochem Biophys Res Commun 148: osteoclast-like cells. J Cell Biol 127:1149–1158. 1129–1136. 64. Watts NB 1999 Clinical utility of biochemical markers of bone 48. Beresford JN, Joyner CJ, Devlin C, Triffitt JT 1994 The effects remodeling. Clin Chem 45:1359–1368. of dexamethasone and 1,25-dihydroxyvitamin D3 on osteogenic 65.
    [Show full text]
  • Intracellular Peptides: from Discovery to Function
    e u p a o p e n p r o t e o m i c s 3 ( 2 0 1 4 ) 143–151 Available online at www.sciencedirect.com ScienceDirect journal homepage: http://www.elsevier.com/locate/euprot Intracellular peptides: From discovery to function a,∗ b a,c d,∗∗ Emer S. Ferro , Vanessa Rioli , Leandro M. Castro , Lloyd D. Fricker a Department of Pharmacology, Biomedical Sciences Institute, University of São Paulo, São Paulo, SP, Brazil b Special Laboratory of Applied Toxicology-CeTICS, Butantan Institute, São Paulo, SP, Brazil c Department of Biophysics, Federal University of São Paulo, São Paulo, SP, Brazil d Department of Molecular Pharmacology and Neuroscience, Albert Einstein College of Medicine, Bronx, NY, USA a r t i c l e i n f o a b s t r a c t Article history: Peptidomics techniques have identified hundreds of peptides that are derived from proteins Received 8 October 2013 present mainly in the cytosol, mitochondria, and/or nucleus; these are termed intracellular Received in revised form peptides to distinguish them from secretory pathway peptides that function primarily out- 29 November 2013 side of the cell. The proteasome and thimet oligopeptidase participate in the production and Accepted 14 February 2014 metabolism of intracellular peptides. Many of the intracellular peptides are common among mouse tissues and human cell lines analyzed and likely to perform a variety of functions Keywords: within cells. Demonstrated functions include the modulation of signal transduction, mito- Peptides chondrial stress, and development; additional functions will likely be found for intracellular Cell signaling peptides.
    [Show full text]
  • Method for Predicting the Occurence of Lung Metastasis in Breast Cancer Patients
    (19) TZZ ¥ __T (11) EP 2 253 721 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 24.11.2010 Bulletin 2010/47 C12Q 1/68 (2006.01) (21) Application number: 10175619.5 (22) Date of filing: 26.02.2008 (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • Lidereau, Rosette HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT 92230, Gennevilliers (FR) RO SE SI SK TR • Driouch, Keltouma Designated Extension States: 93260, Les Lilas (FR) AL BA MK RS • Landemaine, Thomas 92100, Boulogne-Billancourt (FR) (30) Priority: 26.02.2007 EP 07300823 (74) Representative: Catherine, Alain et al (62) Document number(s) of the earlier application(s) in Cabinet Harlé & Phélip accordance with Art. 76 EPC: 7 rue de Madrid 08709219.3 / 2 115 170 75008 Paris (FR) (71) Applicants: Remarks: • INSERM (Institut National de la Santé et de la This application was filed on 07-09-2010 as a Recherche Medicale) divisional application to the application mentioned 75013 Paris (FR) under INID code 62. • Centre Rene Huguenin 92210 Saint-Cloud (FR) (54) Method for predicting the occurence of lung metastasis in breast cancer patients (57) The present invention relates to the prognosis tasis in one or more tissue or organ of patients affected of the progression of breast cancer in a patient, and more with a breast cancer. particularly to the prediction of the occurrence of metas- EP 2 253 721 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 253 721 A1 Description FIELD OF THE INVENTION 5 [0001] The present invention relates to the prognosis of the progression of breast cancer in a patient, and more particularly to the prediction of the occurrence of metastasis in one or more tissue or organ of patients affected with a breast cancer.
    [Show full text]
  • 1 No. Affymetrix ID Gene Symbol Genedescription Gotermsbp Q Value 1. 209351 at KRT14 Keratin 14 Structural Constituent of Cyto
    1 Affymetrix Gene Q No. GeneDescription GOTermsBP ID Symbol value structural constituent of cytoskeleton, intermediate 1. 209351_at KRT14 keratin 14 filament, epidermis development <0.01 biological process unknown, S100 calcium binding calcium ion binding, cellular 2. 204268_at S100A2 protein A2 component unknown <0.01 regulation of progression through cell cycle, extracellular space, cytoplasm, cell proliferation, protein kinase C inhibitor activity, protein domain specific 3. 33323_r_at SFN stratifin/14-3-3σ binding <0.01 regulation of progression through cell cycle, extracellular space, cytoplasm, cell proliferation, protein kinase C inhibitor activity, protein domain specific 4. 33322_i_at SFN stratifin/14-3-3σ binding <0.01 structural constituent of cytoskeleton, intermediate 5. 201820_at KRT5 keratin 5 filament, epidermis development <0.01 structural constituent of cytoskeleton, intermediate 6. 209125_at KRT6A keratin 6A filament, ectoderm development <0.01 regulation of progression through cell cycle, extracellular space, cytoplasm, cell proliferation, protein kinase C inhibitor activity, protein domain specific 7. 209260_at SFN stratifin/14-3-3σ binding <0.01 structural constituent of cytoskeleton, intermediate 8. 213680_at KRT6B keratin 6B filament, ectoderm development <0.01 receptor activity, cytosol, integral to plasma membrane, cell surface receptor linked signal transduction, sensory perception, tumor-associated calcium visual perception, cell 9. 202286_s_at TACSTD2 signal transducer 2 proliferation, membrane <0.01 structural constituent of cytoskeleton, cytoskeleton, intermediate filament, cell-cell adherens junction, epidermis 10. 200606_at DSP desmoplakin development <0.01 lectin, galactoside- sugar binding, extracellular binding, soluble, 7 space, nucleus, apoptosis, 11. 206400_at LGALS7 (galectin 7) heterophilic cell adhesion <0.01 2 S100 calcium binding calcium ion binding, epidermis 12. 205916_at S100A7 protein A7 (psoriasin 1) development <0.01 S100 calcium binding protein A8 (calgranulin calcium ion binding, extracellular 13.
    [Show full text]
  • 2598 Biomineralization of Bone: a Fresh View of the Roles of Non-Collagen
    [Frontiers in Bioscience 16, 2598-2621, June 1, 2011] Biomineralization of bone: a fresh view of the roles of non-collagenous proteins Jeffrey Paul Gorski1 1Center of Excellence in the Study of Musculoskeletal and Dental Tissues and Dept. of Oral Biology, Sch. Of Dentistry, Univ. of Missouri-Kansas City, Kansas City, MO 64108 TABLE OF CONTENTS 1. Abstract 2. Introduction 3. Proposed mechanisms of mineral nucleation in bone 3.1. Biomineralization Foci 3.2. Calcospherulites 3.3. Matrix vesicles 4. The role of individual non-collagenous proteins 4.1. Bone Sialoprotein 4.2. Noggin 4.3. Chordin 4.4. Osteopontin 4.5. Osteopontin, bone sialoprotein, and DMP1 form individual complexes with MMPs 4.6. Bone acidic glycoprotein-75 4.7. Dentin matrix protein1 4.8. Osteocalcin 4.9. Fetuin (alpha2HS-glycoprotein) 4.10. Periostin 4.11. Tissue nonspecific alkaline phosphatase 4.12. Phospho 1 phosphatase 4.13. Ectonucleotide pyrophosphatase/phosphodiesterase 4.14. Biological effects of hydroxyapatite on bone matrix proteins 4.15. Sclerostin 4.16. Tenascin C 4.17. Phosphate-regulating neutral endopeptidase (PHEX) 4.18. Matrix extracellular phosphoglycoprotein (MEPE, OF45) 4.19. Functional importance of proteolysis in activation of transglutaminase and PCOLCE 4.20. Neutral proteases in bone 5. Summary and Perspective 6. Acknowledgements 7. References 1. ABSTRACT The impact of genetics has dramatically affected nteractions which act in positive and negative ways to our understanding of the functions of non-collagenous regulate the process of bone mineralization. Several new proteins. Specifically, mutations and knockouts have examples from the author’s laboratory are provided defined their cellular spectrum of actions.
    [Show full text]
  • Chemical Properties Biological Description Solubility Information
    Data Sheet (Cat.No.T0947) Dexamethason acetate Chemical Properties CAS No.: 1177-87-3 Formula： C24H31FO6 Molecular Weight： 434.51 Appearance： Solid Storage： 0-4℃ for short term (days to weeks), or -20℃ for long term (months). Biological Description Description Dexamethasone Acetate is the acetate salt form of Dexamethasone, a synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. Targets(IC50) Annexin A1: None Glucocorticoid Receptor: None IL receptor: None iNOS: None In vitro Dexamethasone inhibits COX-2 mRNA expression induced by IL-1 in human articular chondrocytes. [1] Dexamethasone suppresses the cyclooxygenase-2 induction by tumor necrosis factor α (TNFα) with an IC50 of 1 nM in MC3T3-E1 cells. Dexamethasone binds to the glucocorticoid receptor and then to the glucocorticoid response element. [2]Dexamethasone (10 μM) induces osteoblastic differentiation of rat bone marrow stromal cell cultures with elevated mRNA expression of alkaline phosphatase osteopontin, bone sialoprotein, and osteocalcin. [3] Dexamethasone (5 μM) treatment decreases proliferation of adult hippocampal neural progenitor cells and SRE-driven gene expression. [5] In vivo Dexamethasone (2 mg/kg) reduces the number of the BrdU-labeled hepatocytes by 80% in male Fischer F344 rats. Dexamethasone (2 mg/kg) pretreatment suppresses the expression of both TNF and IL-6 after partial hepatectomy and significantly reduces the proliferative response of the hepatocytes in male Fischer F344 rats. Dexamethasone also severely diminishes the induction and expansion of oval cells induced by the 2- acetylaminofluorene/partial hepatectomy (AAF/PH) protocol but does not have any effect on the proliferation of the bile duct cells stimulated by bile duct ligation.
    [Show full text]
  • Supplementary Table 2
    Supplementary Table 2. Differentially Expressed Genes following Sham treatment relative to Untreated Controls Fold Change Accession Name Symbol 3 h 12 h NM_013121 CD28 antigen Cd28 12.82 BG665360 FMS-like tyrosine kinase 1 Flt1 9.63 NM_012701 Adrenergic receptor, beta 1 Adrb1 8.24 0.46 U20796 Nuclear receptor subfamily 1, group D, member 2 Nr1d2 7.22 NM_017116 Calpain 2 Capn2 6.41 BE097282 Guanine nucleotide binding protein, alpha 12 Gna12 6.21 NM_053328 Basic helix-loop-helix domain containing, class B2 Bhlhb2 5.79 NM_053831 Guanylate cyclase 2f Gucy2f 5.71 AW251703 Tumor necrosis factor receptor superfamily, member 12a Tnfrsf12a 5.57 NM_021691 Twist homolog 2 (Drosophila) Twist2 5.42 NM_133550 Fc receptor, IgE, low affinity II, alpha polypeptide Fcer2a 4.93 NM_031120 Signal sequence receptor, gamma Ssr3 4.84 NM_053544 Secreted frizzled-related protein 4 Sfrp4 4.73 NM_053910 Pleckstrin homology, Sec7 and coiled/coil domains 1 Pscd1 4.69 BE113233 Suppressor of cytokine signaling 2 Socs2 4.68 NM_053949 Potassium voltage-gated channel, subfamily H (eag- Kcnh2 4.60 related), member 2 NM_017305 Glutamate cysteine ligase, modifier subunit Gclm 4.59 NM_017309 Protein phospatase 3, regulatory subunit B, alpha Ppp3r1 4.54 isoform,type 1 NM_012765 5-hydroxytryptamine (serotonin) receptor 2C Htr2c 4.46 NM_017218 V-erb-b2 erythroblastic leukemia viral oncogene homolog Erbb3 4.42 3 (avian) AW918369 Zinc finger protein 191 Zfp191 4.38 NM_031034 Guanine nucleotide binding protein, alpha 12 Gna12 4.38 NM_017020 Interleukin 6 receptor Il6r 4.37 AJ002942
    [Show full text]
  • Biomimetic Surfaces for Cell Engineering
    Chapter 18 Biomimetic Surfaces for Cell Engineering John H. Slater, Omar A. Banda, Keely A. Heintz and Hetty T. Nie Cell behavior, in particular, migration, proliferation, differentiation, apoptosis, and activation, is mediated by a multitude of environmental factors: (i) extracellular matrix (ECM) properties including molecular composition, ligand density, ligand gradients, stiffness, topography, and degradability; (ii) soluble factors including type, concentration, and gradients; (iii) cell–cell interactions; and (iv) external forc- es such as shear stress, material strain, osmotic pressure, and temperature changes (Fig. 18.1). The coordinated influence of these environmental cues regulate em- bryonic development, tissue function, homeostasis, and wound healing as well as other crucial events in vivo [1–3]. From a fundamental biology perspective, it is of great interest to understand how these environmental factors regulate cell fate and ultimately cell and tissue function. From an engineering perspective, it is of interest to determine how to present these factors in a well-controlled manner to elicit a de- sired cell output for cell and tissue engineering applications. Both biophysical and biochemical factors mediate intracellular signaling cascades that influence gene ex- pression and ultimately cell behavior [4–7], making it difficult to unravel the hierar- chy of cell fate stimuli [8]. Accordingly, much effort has focused on the fabrication of biomimetic surfaces that recapitulate a single or many aspects of the in vivo mi- croenvironment including topography [9–12], elasticity [5], and ligand presentation [13–17], and by structured materials that allow for control over cell shape [18–23], spreading [18, 23–25], and cytoskeletal tension [26–28].
    [Show full text]
  • Papel De Los Receptores De Estrógenos Alfa En El Crecimiento De Carcinomas Mamarios Murinos Con Respuesta Diferencial a Progestágenos
    Tesis Doctoral Papel de los receptores de estrógenos alfa en el crecimiento de carcinomas mamarios murinos con respuesta diferencial a progestágenos Giulianelli, Sebastián Jesús 2009 Este documento forma parte de la colección de tesis doctorales y de maestría de la Biblioteca Central Dr. Luis Federico Leloir, disponible en digital.bl.fcen.uba.ar. Su utilización debe ser acompañada por la cita bibliográfica con reconocimiento de la fuente. This document is part of the doctoral theses collection of the Central Library Dr. Luis Federico Leloir, available in digital.bl.fcen.uba.ar. It should be used accompanied by the corresponding citation acknowledging the source. Cita tipo APA: Giulianelli, Sebastián Jesús. (2009). Papel de los receptores de estrógenos alfa en el crecimiento de carcinomas mamarios murinos con respuesta diferencial a progestágenos. Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires. Cita tipo Chicago: Giulianelli, Sebastián Jesús. "Papel de los receptores de estrógenos alfa en el crecimiento de carcinomas mamarios murinos con respuesta diferencial a progestágenos". Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires. 2009. Dirección: Biblioteca Central Dr. Luis F. Leloir, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires. Contacto: [email protected] Intendente Güiraldes 2160 - C1428EGA - Tel. (++54 +11) 4789-9293 UNIVERSIDAD DE BUENOS AIRES FACULTAD DE CIENCIAS EXACTAS Y NATURALES Departamento de Fisiología, Biología Molecular y Celular PAPEL DE LOS RECEPTORES DE ESTRÓGENOS ALFA EN EL CRECIMIENTO DE CARCINOMAS MAMARIOS MURINOS CON RESPUESTA DIFERENCIAL A PROGESTÁGENOS Tesis presentada para optar por el título de Doctor de la Universidad de Buenos Aires en el área Ciencias Biológicas Sebastián Jesús Giulianelli Director de Tesis: Claudia L.
    [Show full text]